These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7586196)

  • 1. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure.
    Stücker I; Cosme J; Laurent P; Cenée S; Beaune P; Bignon J; Depierre A; Milleron B; Hémon D
    Carcinogenesis; 1995 Nov; 16(11):2759-64. PubMed ID: 7586196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tobacco on lung cancer risk depends on CYP2D6 activity.
    Bouchardy C; Benhamou S; Dayer P
    Cancer Res; 1996 Jan; 56(2):251-3. PubMed ID: 8542575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls.
    Tefre T; Daly AK; Armstrong M; Leathart JB; Idle JR; Brøgger A; Børresen AL
    Pharmacogenetics; 1994 Apr; 4(2):47-57. PubMed ID: 8081413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphism of CYP2D6 and lung cancer risk.
    Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
    Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
    Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
    Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
    Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
    Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
    Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
    Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debrisoquin oxidation genotype and susceptibility to lung cancer.
    Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
    Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
    Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association.
    Caporaso N; DeBaun MR; Rothman N
    Pharmacogenetics; 1995; 5 Spec No():S129-34. PubMed ID: 7581482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.
    Beyeler C; Armstrong M; Bird HA; Idle JR; Daly AK
    Ann Rheum Dis; 1996 Jan; 55(1):66-8. PubMed ID: 8572738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H
    Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
    Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
    Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 genotyping and the association with lung cancer susceptibility.
    Wolf CR; Smith CA; Bishop T; Forman D; Gough AC; Spurr NK
    Pharmacogenetics; 1994 Apr; 4(2):104-6. PubMed ID: 8081411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.